ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Gastrointestinal and Hepatic Pharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1582908
This article is part of the Research TopicEmerging Talents in Frontiers in Pharmacology: Gastrointestinal and Hepatic Pharmacology 2025View all 3 articles
Evaluating the Risk of Osteoporosis-Related Adverse Events with Proton Pump Inhibitors: A Pharmacovigilance Study
Provisionally accepted
- 1Department of Orthopedics, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi Province, China
- 2Department of Orthopedics, The Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences Tongji Shanxi Hospital, Taiyuan, Shanxi Province, China
- 3Second Hospital of Shanxi Medical University, Taiyuan, Shanxi Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Proton pump inhibitors (PPIs) are the most effective antacids and are widely used in the treatment of acid-related diseases. However, the impact of PPIs on bone remains controversial. This study aimed to explore the association between PPIs and osteoporosis-related adverse events in the real world.Data from the United States Food and Drug Administration Adverse Event Reporting System from the first quarter of 2004 to the third quarter of 2024 were included in this study. Four pharmacovigilance analyses, reporting odds ratio (ROR), proportional reporting ratio (PRR), information component (IC), and Empirical Bayes geometric mean (EBGM) were used to explore the association between PPIs use and osteoporosis-related adverse events. In addition, we used the Bonferroni corrected P values and 95% confidence interval (95%CI). Meanwhile, the situation of different age and gender groups was examined using subgroup analysis. Additionally, evoked times and Weibull distributions were used to analyze the data further.At the Primary terms level, esomeprazole, omeprazole and pantoprazole were found to have positive adverse event signals. However, at the overall dimension level of Standardized Medical
Keywords: Proton Pump Inhibitors, Osteoporosis, FAERS, Adverse drug events, drug safety
Received: 25 Feb 2025; Accepted: 27 Jun 2025.
Copyright: © 2025 Di, Yang, Zhao, Chen, Guo, He and Xiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Chuan Xiang, Department of Orthopedics, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.